Why the study?
Does transcatheter aortic valve replacement improve outcomes compared to surgical aortic valve replacement in patients with symptomatic severe aortic valve stenosis?
Does transcatheter aortic valve replacement improve outcomes compared to surgical aortic valve replacement in patients with symptomatic severe aortic valve stenosis?
TAVR is an emerging alternative for inoperable or high-risk patients with severe aortic stenosis, though challenges like paravalvular regurgitation, stroke, and durability remain.
May inform TAVR use in high-risk aortic stenosis; leaves open durability and complication questions for trials.
The standard treatment for symptomatic severe aortic valve stenosis is surgical aortic valve replacement. Over the last decade, transcatheter aortic valve replacement has emerged as an option for patients judged inoperable. It might also constitute an alternative for high-risk patients, even though which patients might benefit from this approach is still being discussed and remains controversial. Transcatheter heart valve replacement is a rapidly spreading technology. However, a number of problems still need to be addressed, such as paravalvular regurgitation, stroke rate, and postoperative conduction disturbances. Further, the durability of transcatheter heart valves remains unclear. Randomized clinical trials and long-term follow-up will help define the role of transcatheter heart valve replacement in aortic stenosis therapy.
No takes yet. Share an insight, caveat, or question.
Goetzenich et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: